OP03 Anti-SARS-CoV2 antibody responses are attenuated in patients with Inflammatory Bowel Disease treated with infliximab
| Autor: | K. Patel, Charles Murray, Andrew Hart, Dermot P.B. McGovern, Peter M. Irving, Jack Bowden, Philip J Smith, J Goodhand, Nicholas A. Kennedy, Shameer Mehta, Nicholas M. Croft, Christopher A. Lamb, Simeng Lin, Jeffrey Butterworth, Richard K Russell, Shaji Sebastian, I. Ahmad, Tim Raine, Christian P. Selinger, Rachel Nice, Desmond Chee, Rachel Cooney, Neil Chanchlani, Charlie W. Lees, Richard Pollok, Timothy J. McDonald, Clarity Ibd Investigators, Claire Bewshea, Nick Powell, Jimmy K. Limdi, Jonathan Macdonald, Klaartje Kok |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
biology
medicine.drug_class business.industry Gastroenterology Scientific Session 1: Sophisticated strategies within reach General Medicine medicine.disease Monoclonal antibody Inflammatory bowel disease Infliximab Vedolizumab Sepsis Immunity Immunology medicine biology.protein Oral presentations Seroconversion Antibody business medicine.drug AcademicSubjects/MED00260 |
| Zdroj: | Journal of Crohn's & Colitis |
| ISSN: | 1876-4479 1873-9946 |
| Popis: | Background Anti-TNF drugs increase the risk of serious respiratory infections and impair protective immunity following pneumococcal, influenza, and viral hepatitis vaccinations. Therefore, we sought to determine whether patients with inflammatory bowel disease treated with infliximab have attenuated serological responses following SARS-CoV-2 infection. Methods CLARITY IBD is a multicentre, prospective observational cohort study. Antibody responses in participants treated with infliximab were compared to a reference cohort treated with vedolizumab, a gut-selective anti-integrin α4β7 monoclonal antibody that is not associated with impaired vaccine responses or increased susceptibility to systemic infections. 6935 patients were recruited from 92 UK hospitals between 22nd September and 23rd December 2020. Nucleocapsid anti-SARS-CoV2 antibodies were measured using the Roche Elecsys assay. Clinical data and serum were collected every 8 weeks. Durability was defined as nonreduction in antibody level by at least 50% from baseline. Results At baseline, rates of symptomatic and proven SARS-CoV-2 infection were similar between groups. Seroprevalence was lower in infliximab- than vedolizumab-treated patients (3.4% [161/4685], vs 6.0% [134/2250], p Conclusion Seroprevalence, seroconversion in PCR-confirmed cases, and the magnitude and durability of anti-SARS-CoV2 antibodies were reduced in infliximab- compared with vedolizumab-treated patients. Serological testing and virus surveillance should be considered in patients treated with anti-TNF drugs to detect suboptimal vaccine responses, persistent infection, and viral evolution to inform public health policy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|